<DOC>
	<DOCNO>NCT00548431</DOCNO>
	<brief_summary>The present pharmacokinetic ( PK ) -pharmacodynamic ( PD ) study explore toxicity antileukemic response initial 3 month individualise therapy child young adult acute lymphoblastic leukemia ( ALL ) . The investigator individual toxicity-titrated basis attempt increase dose intensity 6-mercaptopurine used two-months post-remission treatment phase low risk childhood ALL . This perform together continuous PEG-ASP ( every 2nd week ) intersperse HD-MTX ( 5 g/m^2 ) every 3rd week . Thus , trial also test feasibility particular drug combination .</brief_summary>
	<brief_title>NOPHO ALL-2008 Pilot Study Consolidation Therapy Children Adolescents With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>In addition detail also explore - relationship post-HD-MTX MRD-levels dose 6MP , TPMT-activity , DNA-6TGN , E-6TGN , E-MeMP , E-MTX , presence ASP-antibodies , - early development anti-ASP antibody continuous PEG-ASP therapy . The study could improve understand pharmacodynamics 6MP/HD-MTX interaction combination PEG-ASP .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<criteria>Blineage ALL 117.9 year WBC &lt; 100 , clinical remission obtain day 2 Written consent participation . ( 9 ; 22 ) Hypodiploidy 11q23aberrations TPMTdeficiency Intolerance MTX 6MP</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Leukemia , Lymphocytic , Acute [ C04.557.337.428.511 ]</keyword>
	<keyword>6-mercaptopurine</keyword>
	<keyword>methotrexate</keyword>
	<keyword>asparaginase</keyword>
</DOC>